Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 2/2018

01.02.2018 | Adis Drug Evaluation

Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C

verfasst von: Lesley J. Scott

Erschienen in: Drugs | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Oral once-daily, fixed-dose, ledipasvir/sofosbuvir (Harvoni®) [± ribavirin] is approved in several countries for the treatment of chronic hepatitis C (CHC) in adults and adolescents aged 12 to < 18 years, with direct-acting antiviral (DAA) regimens resulting in a paradigm shift in the treatment of the disease. In the clinical trial and/or clinical practice setting, ledipasvir/sofosbuvir (± ribavirin) was associated with high sustained virological response rates 12 weeks post-treatment (SVR12) in treatment-naive and -experienced adults and adolescents with chronic hepatitis C virus (HCV) genotype (GT) 1 infection, including in those with compensated cirrhosis or who were co-infected with HIV. SVR12 rates in real-world studies were consistent with those in trials. In other trials, ledipasvir/sofosbuvir (± ribavirin) was associated with high SVR12 rates in various CHC populations, including patients with HCV GT2, 3, 4, 5 or 6 infection, cirrhosis, pre and/or post liver or renal transplantation, inherited blood disorders or failure after prior DAA and/or interferon therapy. Thus, ledipasvir/sofosbuvir (± ribavirin) is a valuable effective and generally well tolerated option for adolescent and adult patients with HCV GT1, 4, 5 or 6 infection, including those with HIV co-infection or cirrhosis, with evidence also supporting its use in patients with chronic HCV GT2 or 3 infection.
Literatur
1.
Younossi Z, Birerdinc A, Henry L. Hepatitis C infection: a multi-faceted systemic disease with clinical, patient-reported and economic consequences. J Hepatol. 2016;65:S109–19.CrossRefPubMed
2.
Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl S1):47–7.
3.
Majumdar A, Kitson MT, Roberts SK. Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy. Drugs. 2015;75:823–34.CrossRefPubMed
4.
5.
German P, Mathias A, Brainard D, et al. Clinical pharmacokinetics and pharmacodynamics of ledipasvir/sofosbuvir, a fixed-dose combination tablet for the treatment of hepatitis C. Clin Pharmacokinet. 2016;55(11):1337–51.CrossRefPubMed
6.
Keating GM. Ledipasvir/sofosbuvir: a review of its use in chronic hepatitis C. Drugs. 2015;75(6):675–85.CrossRefPubMed
7.
Cheng G, Tian Y, Doehle B, et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother. 2016;60(3):1847–53.CrossRefPubMedPubMedCentral
8.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.CrossRefPubMed
9.
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.CrossRefPubMed
10.
Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.CrossRefPubMed
11.
Mizokami M, Dvory-Sobol H, Izumi N, et al. Resistance analyses of Japanese hepatitis co-infected patients receiving sofosbuvir or ledipasvir/sofosbuvir containing regimens in phase 3 studies. J Viral Hepat. 2016;23(10):780–8.CrossRefPubMed
12.
Wyles D, Dvory-Sobol H, Svarovskaia ES, et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol. 2017;66(4):703–10.CrossRefPubMed
13.
Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(3):501-12.e1.
14.
Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66:910–8.CrossRefPubMed
15.
Kan H, Imamura M, Kawakami Y, et al. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. J Med Virol. 2017;89(11):1963–72.CrossRefPubMed
16.
Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677–90.CrossRefPubMed
17.
Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with or without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645–53.CrossRefPubMed
18.
Kowdley KV, An D, Pang PS, et al. Analysis of subgroup differences in the ION-3 trial of ledipasvir-sofosbuvir in chronic hepatitis C infection. Open Forum Infect Dis. 2015;2(2):1–2.CrossRef
19.
Wilder JM, Jeffers LJ, Ravendhran N, et al. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology. 2016;63(2):437–44.CrossRefPubMed
20.
Saab S, Park SH, Mizokami M, et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016;63(4):1112–9.CrossRefPubMed
21.
Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62(1):79–86.CrossRefPubMed
22.
Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatol. 2015;61(6):1798–808.CrossRef
23.
Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology. 2015;61(6):1793–7.CrossRefPubMed
24.
Lawitz E, Pockros P, Yang JC, et al. Ledipasvir/sofosbuvir regimens for the retreatment of patients who failed sofosbuvir-based regimens [abstract no. O-011]. Hepatol Int. 2016;10(Suppl 1):S9.
25.
26.
Akuta N, Sezaki H, Suzuki F, et al. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. J Med Virol. 2017;89(7):1248–54.CrossRefPubMed
27.
Kowdley KV, Sundaram V, Jeon CY, et al. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology. 2017;65(4):1094–103.CrossRefPubMed
28.
Butt AA, Yan P, Shaikh OS, et al. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES. Liver Int. 2016;36(9):1275–83.CrossRefPubMed
29.
Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-40.e5.
30.
Tapper EB, Bacon BR, Curry MP, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017;24(1):22–7.CrossRefPubMed
31.
Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893–9.CrossRefPubMed
32.
Curry MP, Tapper EB, Bacon B, et al. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther. 2017:1–9.
33.
Backus LI, Belperio PS, Shahoumian TA, et al. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64(2):405–14.CrossRefPubMed
34.
Backus LI, Belperio PS, Shahoumian TA, et al. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine clinical practice. Aliment Pharmacol Ther. 2016;44:400–10.CrossRefPubMed
35.
36.
Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371–8.CrossRefPubMed
37.
Younossi ZM, Stepanova M, Balistreri W, et al. Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with sofosbuvir and ledipasvir. J Ped Gastroenterol Nutr. 2018;66(1):1112–6.CrossRef
38.
Gane EJ, Hyland RH, Yang Y, et al. Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. Gastroenterology. 2017;152(6):1366–71.CrossRefPubMed
39.
Feld JJ, Ramji A, Shafran SD, et al. Ledipasvir-sofosbuvir plus ribavirin in treatment-naive patients with hepatitis C virus genotype 3 infection: an open-label study. Clin Infect Dis. 2017;65(1):13–9.CrossRefPubMed
40.
Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149(6):1454–61.CrossRefPubMed
41.
Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016;64(4):1049–56.CrossRefPubMed
42.
Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept phase 2a cohort study. Lancet Infect Dis. 2015;15(9):1049–54.CrossRefPubMedPubMedCentral
43.
Abergel A, Asselah T, Metivier S, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16(4):459–64.CrossRefPubMed
44.
Nguyen MH, Trinh H, Do S, et al. Open label study of 8 vs. 12 weeks of ledipasvir/sofosbuvir in genotype 6 treatment naive or experienced patients. Am J Gastroenterol. 2017;112(12):1824–31.CrossRefPubMed
45.
Asahina Y, Itoh Y, Ueno Y, et al. Ledipasvir/sofosbuvir in the treatment of Japanese patients with chronic HCV genotype 2 infection [abstract no. 1184]. Hepatology. 2017;66(1 Suppl):638A.
46.
Pol S, ANRS/AFEF HEPATHER study group. Safety and efficacy of the combination sofosbuvir-ledipasvir in HCV mono-infected patients from the French Cohort ANRS CO22 HEPATHER [abstract no. 1087]. Hepatology. 2017;66(1 Suppl):582A.
47.
Cornberg M, Petersen J, Schober A, et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2017;45(5):688–700.CrossRefPubMed
48.
Tsertsvadze T, Chkhartishvilli N, Abutidze A, et al. Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia [abstract no.1167]. Hepatology. 2017;66(1 Suppl):627-8A.
49.
Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685–97.CrossRefPubMed
50.
Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–59.CrossRefPubMed
51.
52.
Cooper CL, Naggie S, Saag MS, et al. Successful retreatment of HCV/HIV-coinfected patients who failed 12 weeks of LDV/SOF. Clin Infect Dis. 2016;63:528–31.CrossRefPubMedPubMedCentral
53.
Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat. 2016;23(11):857–65.CrossRefPubMed
54.
Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397–404.CrossRefPubMed
55.
Hagiwara S, Nishida N, Watanabe T, et al. Outcome of combination therapy with sofosbuvir and ledipasvir for chronic type C liver disease. Oncology. 2017;92(Suppl 1):3–9.CrossRefPubMed
56.
57.
Ferreira VL, Assis Jarek NA, Tonin FS, et al. Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: a pairwise meta-analysis. J Gastroenterol Hepatol. 2017;32(4):749–55.CrossRefPubMed
58.
Younossi ZM, Stepanova M, Pol S, et al. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int. 2016;36(1):42–8.CrossRefPubMed
59.
60.
Kwok RM, Ahn J, Schiano TD, et al. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Liver Transpl. 2016;22(11):1536–43.CrossRefPubMed
61.
Saxena V, Khungar V, Verna EC, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology. 2017;66(4):1090–101.CrossRefPubMed
62.
Colombo M, Aghemo A, Liu H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166(2):109–17.CrossRefPubMed
63.
Stedman CAM, Hyland RH, Ding X, et al. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2016;22(2):214–7.CrossRef
64.
Walsh CE, Workowski K, Terrault NA, et al. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia. 2017;23(2):198–206.CrossRefPubMed
65.
Mangia A, Sarli R, Gamberini R, et al. Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment Pharmacol Ther. 2017;46(4):424–31.CrossRefPubMed
66.
Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology. 2015;62(1):25–30.CrossRefPubMed
67.
68.
Rosenblatt R, Kumar S, Mehta A, et al. Baseline creatinine clearance is a predictor of worsening renal function while on treatment with sofosbuvir-ledipasvir [abstract no. Su1464]. Gastroenterology. 2016;150(4 Suppl. 1):S1107.
69.
70.
71.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2016;61(1):153–94.
72.
European Medicines Agency. Vosevi (sofosbuvir, velpatasvir and voxilaprevir) 400 mg/100 mg/10 mg film coated tablets: summary of product characteristics. 2017. http://​www.​ema.​europa.​eu. Accessed 4 Nov 2017.
73.
Carter W, Connelly S, Struble K. Reinventing HCV treatment: past and future perspectives. J Clin Pharmacol. 2017;57(3):287–96.CrossRefPubMed
Metadaten
Titel
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C
verfasst von
Lesley J. Scott
Publikationsdatum
01.02.2018
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 2/2018
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-018-0864-z

Weitere Artikel der Ausgabe 2/2018

Drugs 2/2018 Zur Ausgabe

Review Article

Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting

Correction

Correction to: Tocilizumab: A Review in Rheumatoid Arthritis

Leading Article

Hypermutated Tumors and Immune Checkpoint Inhibition

AdisInsight Report

Semaglutide: First Global Approval

Review Article

Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents

Adis Drug Evaluation

MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years